CD247 and neoplasm: In 2018, Li et al. found that the CAR constructs with an optimal design for NK cells, consisting of the NKG2D transmembrane domain, the 2B4 co-stimulatory domain, and the CD3ζ signaling domain, may confer potent anti-tumor activity in NK cells.